Agustí C, Xaubet A, Ballester E, Alarcón A, Picado C
Servei de Pneumologia, Hospital Clinic, Facultat de Medicina, Barcelona, Spain.
Thorax. 1993 Jan;48(1):68-9. doi: 10.1136/thx.48.1.68.
A report has recently been published concerning a patient with a cryptogenic fibrosing alveolitis who showed a striking improvement after being treated with the antiviral drug ribavirin (tribavirin, Virazid). The objective of this study was to further evaluate, in an open trial, the efficacy of rivabirin in cryptogenic fibrosing alveolitis.
Ten patients (eight women) with advanced cryptogenic fibrosing alveolitis received aerosolised ribavirin (6 g/day for 15 days). Chest radiographs, lung function, and severity of dyspnoea were evaluated before and after two weeks of rivabirin treatment and also at three and 12 months.
No differences in radiographs, lung function impairment, or severity of dyspnoea were found after treatment. No side effects were detected.
Administration of high doses of aerosolised ribavirin has no beneficial effects in patients with advanced cryptogenic fibrosing alveolitis.
最近发表了一份关于一名隐源性纤维性肺泡炎患者的报告，该患者在接受抗病毒药物利巴韦林（三氮唑核苷，病毒唑）治疗后有显著改善。本研究的目的是在一项开放性试验中进一步评估利巴韦林对隐源性纤维性肺泡炎的疗效。
10例（8名女性）晚期隐源性纤维性肺泡炎患者接受雾化利巴韦林治疗（6克/天，共15天）。在利巴韦林治疗两周前后以及3个月和12个月时评估胸部X线片、肺功能和呼吸困难严重程度。
治疗后在胸部X线片、肺功能损害或呼吸困难严重程度方面未发现差异。未检测到副作用。
给予高剂量雾化利巴韦林对晚期隐源性纤维性肺泡炎患者没有有益效果。
